Abstract
The immunosuppressive drugs Cyclosporine A (CSA) and prednisolone are widely used to prevent graftversus- host-disease (GVHD) after allogenetic stem cell transplantation (allo-SCT). However, it remains to be elucidated whether these drugs have an effect on the balance of effector cells and CD4+CD25+ regulatory T cells (Tregs) which determines the development of stable allograft tolerance. In the current study, we found that proliferation, activation and function of T cells especially for virus-specific CD8+ T cells and Tregs were inhibited by CSA and prednisolone in a dosedependent manner. These effects were associated with lower secretion of cytokines and arresting T cells in the G0/G1 phase of cell cycle. Moreover, CSA and prednisolone could reduce the expression of FOXP3 and suppressive function of Tregs. Our data indicated that CSA and prednisolone impaired the development and function of CD8+ T cells as well as Tregs in a similar way suggesting that CSA and prednisolone might increase the susceptibility to develop viral diseases and block the potential induction of immune tolerance in clinical settings.
Keywords: T cells, cyclosporine A, prednisolone
Current Signal Transduction Therapy
Title: The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells
Volume: 4 Issue: 3
Author(s): Fei Fei, Yingzhe Yu, Anita Schmitt, Markus Thomas Rojewski, Baoan Chen, Marlies Gotz, Philippe Guillaume, Donald Bunjes and Michael Schmitt
Affiliation:
Keywords: T cells, cyclosporine A, prednisolone
Abstract: The immunosuppressive drugs Cyclosporine A (CSA) and prednisolone are widely used to prevent graftversus- host-disease (GVHD) after allogenetic stem cell transplantation (allo-SCT). However, it remains to be elucidated whether these drugs have an effect on the balance of effector cells and CD4+CD25+ regulatory T cells (Tregs) which determines the development of stable allograft tolerance. In the current study, we found that proliferation, activation and function of T cells especially for virus-specific CD8+ T cells and Tregs were inhibited by CSA and prednisolone in a dosedependent manner. These effects were associated with lower secretion of cytokines and arresting T cells in the G0/G1 phase of cell cycle. Moreover, CSA and prednisolone could reduce the expression of FOXP3 and suppressive function of Tregs. Our data indicated that CSA and prednisolone impaired the development and function of CD8+ T cells as well as Tregs in a similar way suggesting that CSA and prednisolone might increase the susceptibility to develop viral diseases and block the potential induction of immune tolerance in clinical settings.
Export Options
About this article
Cite this article as:
Fei Fei, Yu Yingzhe, Schmitt Anita, Rojewski Thomas Markus, Chen Baoan, Gotz Marlies, Guillaume Philippe, Bunjes Donald and Schmitt Michael, The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells, Current Signal Transduction Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157436209789057502
DOI https://dx.doi.org/10.2174/157436209789057502 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Nanotechnology, A Tool for Diagnostics and Treatment of Cancer
Current Topics in Medicinal Chemistry Interferon-α Treatment in Systemic Mastocytosis
Current Drug Targets Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic Target in Chronic Lymphocytic Leukemia
Current Topics in Medicinal Chemistry Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Nanoparticles for Cancer Targeting: Current and Future Directions
Current Drug Delivery On the Origin of Epidermal Cancers
Current Molecular Medicine Machine Learning for Childhood Acute Lymphoblastic Leukaemia Gene Expression Data Analysis: A Review
Current Bioinformatics Editorial (Hot Topic:Aspergillosis: New Insights into Disease, Diagnostic and Treatment)
Current Pharmaceutical Design Neutrophil MiRNA-128-3p is Decreased During Active Phase of Granulomatosis with Polyangiitis
Current Genomics <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Lichen Depsidones as Potential Novel Pharmacologically Active Compounds
Mini-Reviews in Organic Chemistry The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry